Clinical trial · Observational
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
Multicentric Multinational Observational Study to Describe the Shift in Stage at Diagnosis of Lung Cancer. No Direct Recruitment of Patients or Administration of Study Medication.
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as large increase in community chest radiography referral rates in response to public awareness campaigns, as well as unintentional detections through cardiac CT(computed tomography) angiograms, or screening for coronary disease may help in detecting the disease at earlier curable stages. Availability and increased access to novel therapies increase the likelihood of an early-stage diagnosis aiming for improved survival.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lung Cancer | Malignant Lung Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (3)
- measure
- Early stage (stage I and II with [N0])
- timeFrame
- 5 years
- description
- Number and percentage of patients diagnosed with Early stage (stage I and II with \[N0\]) from baseline year until EOS
- measure
- Locally advanced (stage II and III [N+])
- timeFrame
- 5 years
- description
- Number and percentage of patients diagnosed with Locally advanced (stage II and III \[N+\]) from baseline year until EOS
- measure
- Late stage (stage IV [M1])
- timeFrame
- 5 years
- description
- Number and percentage of patients diagnosed with Late stage (stage IV \[M1\]) from baseline year until EOS
Secondary outcomes (4)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adult female and male patients ≥18 years old. * Confirmed diagnosis of lung cancer (either cytologically or histologically) Exclusion Criteria: * Patients presenting with recurrent or relapsed lung cancer. * Patients with a concomitant cancer at the time of diagnosis of lung cancer, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms: a cancer will be considered concomitant if it occurs within 5 years of lung cancer diagnosis.
References
Publications (0)
Data not yet available